The development of c-Abl inhibitors, such as Ponatinib, has opened promising therapeutic avenues for PD, with initial studies demonstrating their potential to slow disease progression and alleviate symptoms [15, 16]. This evidence concerns the gene ABL1 and Parkinson disease.